Search Login Register

ibritumomab tiuxetan (Zevalin) Summary

Description: 90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma

Also Known As: Zevalin; IDEC brand of ibritumomab tiuxetan; IDEC-Y2B8; yttrium-90-ibritumomab tiuxetan

Networked: 236 relevant articles (32 outcomes, 63 trials/studies) for this Drug

Key Diseases for which ibritumomab tiuxetan is Relevant

  1. Non-Hodgkin Lymphoma (Lymphosarcoma) : 12 outcomes 24 studies in 105 results
  2. Lymphoma (Lymphomas) : 7 outcomes 13 studies in 47 results
  3. Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) : 5 outcomes 9 studies in 29 results
  4. B-Cell Lymphoma (Lymphoma, B Cell) : 4 outcomes 7 studies in 25 results
  5. Thrombocytopenia (Thrombopenia) : 2 outcomes 6 studies in 13 results
Show All >>

Drugs Related to ibritumomab tiuxetan

  1. ibritumomab tiuxetan (Zevalin)
  2. rituximab (Mabthera)
  3. Yttrium
  4. Etoposide (VP 16)
  5. Melphalan (Alkeran)
  6. fludarabine
  7. Cytarabine (Cytosar-U)
  8. Carmustine (FIVB)
  9. Cyclophosphamide (Cytoxan)
  10. Mitoxantrone (Novantrone)
Show All >>

Therapies Related to ibritumomab tiuxetan

  1. Radioimmunotherapy
  2. Drug Therapy (Chemotherapy)
  3. Stem Cell Transplantation
  4. Radiotherapy
  5. Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.